Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 29, 2012

Primary Completion Date

May 24, 2018

Study Completion Date

May 24, 2018

Conditions

Primary MyelofibrosisSecondary MyelofibrosisMyeloid Malignancies

Interventions

DRUG

Imetelstat

Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.

Trial Locations (1)

Rochester